Akuffo H, Darce M, Maasho K, Berhan T Y
Department of Infectious Diseases, Karolinska Institute, Huddinge Hospital, Sweden.
Am J Trop Med Hyg. 1995 Jul;53(1):16-22.
Skin test reactivity to two commercial preparations of Leishmania major leishmanin was evaluated in leishmaniasis patents from Ethiopia (L. aethiopica) and Nicaragua (probably L. braziliensis complex). The purpose of using different preparations of L. major was to evaluate whether L. major skin test antigens could generally be used to detect leishmaniasis due to L. aethiopica and L. braziliensis. One preparation was superior in identifying the majority (83-90%) of confirmed cases of local cutaneous leishmaniasis (LCL) from Ethiopia. In vitro responses to promastigotes of Leishmania spp. correlated well with leishmanin positivity to this preparation. The skin test antigen, which performed less well (showing a positive result in only 50% of the LCL patients), showed promise when used to test active and cured cases of leishmaniasis in Nicaragua (positive result in 92% of the active and cured patents). Cross-reacting Leishmania spp. may be considered for use in the preparation of standardized leishmanin antigen; however, differences in the commercial preparation or the diluent in which the parasites are prepared may affect antigenicity and thus its efficacy in detecting different forms of leishmaniasis in different geographic areas.
在来自埃塞俄比亚(埃塞俄比亚利什曼原虫)和尼加拉瓜(可能是巴西利什曼原虫复合体)的利什曼病患者中,评估了对两种商业制备的硕大利什曼原虫利什曼菌素的皮肤试验反应性。使用不同的硕大利什曼原虫制剂的目的是评估硕大利什曼原虫皮肤试验抗原是否通常可用于检测由埃塞俄比亚利什曼原虫和巴西利什曼原虫引起的利什曼病。一种制剂在识别埃塞俄比亚大多数(83%-90%)确诊的局部皮肤利什曼病(LCL)病例方面表现更优。对利什曼原虫前鞭毛体的体外反应与对该制剂的利什曼菌素阳性反应密切相关。在尼加拉瓜用于检测利什曼病活动期和治愈病例时,表现较差的皮肤试验抗原(仅在50%的LCL患者中呈阳性结果)显示出了前景(在92%的活动期和治愈患者中呈阳性结果)。可考虑使用交叉反应的利什曼原虫物种来制备标准化的利什曼菌素抗原;然而,商业制剂或制备寄生虫时所用稀释剂的差异可能会影响抗原性,进而影响其在检测不同地理区域不同形式利什曼病中的功效。